Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2017-09-25 Director's Dealing
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-09-25 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the appointment of a new President and CEO, Mr. Peter Hoang, and changes in the Board of Directors, including the expansion of the board and amendments to employment agreements. There are no financial statements or detailed financial performance data included. The primary subject is management changes and related employment agreements. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not an annual or quarterly report, audit report, earnings release, or any other category. Therefore, the correct classification is MANG with high confidence.
2017-09-25 English
DEL AM
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-3 filed by TapImmune Inc. It includes language to delay the effective date of the registration statement as per SEC Rule 473. The content is related to a regulatory filing about a securities registration amendment, not a financial report, earnings release, or other specific report types. The document length is short (1666 characters) and is primarily a formal communication with the SEC about the registration statement amendment. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2017-09-22 English
S-3/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A, which is a registration statement filed with the SEC under the Securities Act of 1933. It is used to register securities for resale by selling stockholders and includes detailed information about the securities, selling stockholders, and terms of the offering. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and resale. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the securities offering, not just an announcement or notice. Therefore, the appropriate classification is CAP with high confidence.
2017-09-22 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It includes detailed information about the registration of common stock and warrants for resale by selling shareholders, including exercise prices, terms, and conditions. The document is a registration statement prospectus, which is a capital markets filing related to securities offerings and fundraising activities. It is not an annual report, earnings release, or any other financial report type. It is also not a simple announcement or certification but a full registration statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2017-09-20 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 29, 2017, by TapImmune Inc. It reports the submission of matters to a vote of security holders at the 2017 annual meeting, including election of directors, advisory votes on executive compensation, approval of stock ownership plans, and ratification of auditors. The document contains detailed voting results for multiple proposals. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting. The document is not an Annual Report, Audit Report, or Management Report, nor is it a simple announcement or certification. It contains substantive voting data and is not merely a notice or proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2017-09-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.